DrugPatentWatch Database Preview
TAFINLAR Drug Profile
When do Tafinlar patents expire, and what generic alternatives are available?
Tafinlar is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and three patent family members in thirty-nine countries.
The generic ingredient in TAFINLAR is dabrafenib mesylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the dabrafenib mesylate profile page.
Summary for TAFINLAR
| International Patents: | 103 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 68 |
| Clinical Trials: | 19 |
| Patent Applications: | 63 |
| Drug Prices: | Drug price information for TAFINLAR |
| DailyMed Link: | TAFINLAR at DailyMed |
Generic Entry Opportunity Date for TAFINLAR
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for TAFINLAR
Synonyms for TAFINLAR
| (GSK2118436) pound notDabrafenib |
| 1195765-45-7 |
| 4CA-0431 |
| AB0087834 |
| AB01565833_02 |
| ABP001006 |
| AC-25889 |
| AK160990 |
| AKOS024463285 |
| AKOS032950004 |
| AOB87722 |
| API01001 |
| AS-19634 |
| AX8262770 |
| BC297817 |
| BDBM50428286 |
| BFSMGDJOXZAERB-UHFFFAOYSA-N |
| BRD-K09951645-066-01-2 |
| C23H20F3N5O2S2 |
| CHEBI:75045 |
| CHEMBL2028663 |
| CS-0692 |
| D05ROI |
| D0BO9V |
| D10064 |
| Dabrafenib |
| Dabrafenib (BRAF inhibitor) |
| Dabrafenib (Free Base) |
| Dabrafenib (GSK2118436) |
| Dabrafenib (USAN) |
| Dabrafenib [USAN:INN] |
| dabrafenib mesilate |
| Dabrafenib Mesylate (GSK-2118436) |
| DABRAFENIB, KB-57246 |
| DB08912 |
| DTXSID20152499 |
| EX-A1320 |
| FD5028 |
| GSK 2118436 |
| GSK 2118436A |
| GSK2118436A |
| GTPL6494 |
| HE300679 |
| HMS3656D12 |
| HY-14660 |
| J-004153 |
| KB-01625 |
| KB-57246 |
| KS-000005OR |
| MFCD17215684 |
| MLS006011052 |
| MolPort-028-720-422 |
| N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide |
| N-(3-(5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide |
| N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfo |
| N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide |
| N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide |
| N-{3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl}-2,6- difluorobenzenesulfonamide |
| N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide |
| N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide |
| N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butylthiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide |
| NCGC00346716-01 |
| P06 |
| QCR-129 |
| QGP4HA4G1B |
| S2807 |
| SCHEMBL806377 |
| SMR004702844 |
| Tube719 |
| UNII-QGP4HA4G1B |
| W-5688 |
| Y1871 |
| ZINC68153186 |
US Patents and Regulatory Information for TAFINLAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-002 | May 29, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-002 | May 29, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Novartis Pharms Corp | TAFINLAR | dabrafenib mesylate | CAPSULE;ORAL | 202806-001 | May 29, 2013 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for TAFINLAR
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Peru | 19522009 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2011047238 | ➤ Sign Up |
| Peru | 10932012 | ➤ Sign Up |
| Dominican Republic | P2012000091 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for TAFINLAR
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0140036 00120 | Estonia | ➤ Sign Up | PRODUCT NAME: TRAMETINIIB;REG NO/DATE: EU/1/14/931 02.07.2014 |
| 2014 00055 | Denmark | ➤ Sign Up | PRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140630 |
| 2014039,C1761528 | Lithuania | ➤ Sign Up | PRODUCT NAME: TRAMETINIBAS; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140630 |
| 00701 | Netherlands | ➤ Sign Up | PRODUCT NAME: TRAMETINIB, DESGEWENST IN DE VORM VAN EEN FRAMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140702 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
